Vietnam Investment Review on MSN
Ascletis Acne Drug Shows Positive Phase Three Results
HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...
Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne drug denifanstat (ASC40). Read more here.
“The influencers do not lie,” says one reviewer. “This stuff is magic!” ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...
A new study published in the Annals of Medicine and Surgery showed that the severity of acne was not significantly correlated ...
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The ...
Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new efficacy, spurring investor caution. SGMT’s Denifanstat, a first-in-class FASN ...
The Standard Shopping Shortlist: What to shop, see and know in February 2026 - The hot-off-the-press launches and shiny ...
From contrast therapy to rhythmic health, experts are placing renewed focus on recovery, rest, and repair. Read on for some ...
WEIFANG, SHANDONG, CHINA, January 21, 2026 /EINPresswire.com/ -- 1. Rising Global Demand for PDT LED Light Therapy As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results